BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that its Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO (vosoritide) in children with hypochondroplasia met ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE